



Cannabis Life Sciences Company



Corporate Presentation

December 2019

FORWARD LOOKING STATEMENTS


Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

REVIVE THERAPEUTICS

- **Emerging cannabis life sciences company**
- **Developing novel cannabis-based therapies to treat liver, inflammatory, and rare diseases**
- **Robust cannabis-based patent and product portfolio targeting multi-billion market opportunities**
- **Significantly undervalued compared to cannabis-based biopharma peers**
- **Unique opportunity to invest in the next evolution of the cannabis market**

PHARMA CANNABIS MARKET OPPORTUNITY

Up to \$180 Billion¹



76% of physicians in favor of the use of marijuana for medicinal purposes

Cannabis has shown the potential to treat a broad range of diseases

Pain	Alzheimer's	Hepatitis
Autism	Parkinson's	CNS Disorders
Epilepsy	Cancer	Crohn's & Colitis
Glaucoma	Liver	Arthritis
Nausea	Lupus	Tourette's
Concussions	Migraines	AIDS / HIV
Sleep Disorders	Skin disorders	Kidney
Muscle spasm	PTSD	Cachexia

...also over 100 diseases

¹ At Maturity, Source: Eight Capital, "The Value Case for Investing in the Cannabis Sector".

² Source: Grandview Research 2017, N Engl J Med 2013; 368:e30 May 30, 2013

CANNABINOID PHARMACEUTICAL STRATEGY



Cannabinoids may represent ~10% of \$20 Billion specialty pharma market over next 5 years¹



Targeting Inflammation and Rare Diseases



Novel Cannabinoid Delivery System



FDA Orphan Designations



CANNABINOID DELIVERY TECHNOLOGY

- **Delivering naturally extracted cannabis with novel combination of composites via multiple delivery formats**
 - **Tannin** (plant-based) - antibacterial, antifungal, antioxidant & wound healing properties
 - **Chitosan** (shrimp-based) - blood-clotting & antimicrobial properties
- **Unique attributes of composites for potential synergistic and better therapeutic effect with cannabis**
 - Releases (rapid, controlled, sustained), improved bioavailability, no first-pass metabolism
- **Allows for potential best-in-class products**
 - Accelerate reduction of inflammation & healing rate, reduce & protect from infections



SCIENCE AND IP DRIVEN CANNABIS-BASED PRODUCTS

4

Exclusive licenses to patents

Cannabinoid Patents

Compelling Features

Delivery System

Improved bioavailability

Liver disease

Delivery options (oral, buccal, topical)



Rapid, Sustained, Controlled delivery

Improved safety, effectiveness, compliance

Title	Patent No.	Status
Cannabinoid Delivery System Tannin-chitosan composites	US 8642088	Issued on February 4, 2014
Cannabinoid Delivery System Tannin-chitosan composites	US 9545423	Issued on January 17, 2017
Cannabinoid Delivery System Tannin-chitosan composites	US 10104888	Issued on October 23, 2018
Use of Cannabidiol in the Treatment of Autoimmune Hepatitis	US 8242178	Issued on August 14, 2012


PRODUCT PIPELINE

CANNABINOID PHARMACEUTICALS

Product Candidates		Target Indications	Addressable Market Size	US Population	Development Status
Topical CBD		Dermatitis, Psoriasis, Acne Wound Care	\$25Bn \$35Bn	+40mm 12mm	Preclinical
Oral/IV CBD		Liver diseases: Autoimmune Hepatitis, Nonalcoholic steatohepatitis	\$19.5Bn	30mm	Preclinical

LIVER DISEASE OPPORTUNITY

- Potential \$19.5Bn market by 2022; affecting +30mm people in U.S.
- Focus on Autoimmune Hepatitis (AIH) and Nonalcoholic steatohepatitis (NASH)
- AIH - rare disease (~ 76k patients in US) causing liver inflammation
 - Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%*
- NASH – fatty liver, most common liver disease (3-5% adults)
 - No approved therapeutic for NASH; Patients increased risk of cirrhosis, expected to be leading cause of liver transplants



Pharma deals in liver diseases:

- Allergan/Tobira \$1.7Bn acquisition
- Novartis/Conatus \$650mm license
- Gilead/Nimbus \$1.2Bn acquisition


Source:

World J Gastroenterol. 2010 Feb 28; 16(8): 934–947

Global NASH Market July 2017 Acute Market Reports

INFLAMMATORY SKIN DISEASE OPPORTUNITY

- **Inflammatory skin diseases from immune system reactions**
- **Unmet medical need requiring new treatment options**
 - Current treatments are inadequate, have unwanted side effects profiles, and expensive
- **Dermatitis (Eczema) Market Opportunity**
 - ~ 31mm patients in the U.S. and ~ \$4Bn market size
- **Psoriasis Market Opportunity**
 - ~ 7.5mm patients in the U.S. and ~ \$20Bn market size
- **Acne Market Opportunity**
 - ~\$4.9Bn market size in 2016 and potential of ~\$7.3Bn by 2025





Pharma deals in skin diseases:

- Purdue/Exicure \$790mm license
- Astra/Valeant \$445mm license
- Allergan/Vitae \$639mm deal

WOUND CARE OPPORTUNITY

- Global wound care market estimated at USD \$35Bn by 2022
- Unmet medical need requiring new treatment options
- Types of wounds include surgical scars, burns and diabetic foot and pressure ulcers
- **Diabetic Foot and Pressure Ulcers Opportunity**
 - USD\$4.9Bn by the end of 2024 from US\$2.8Bn in 2015
 - 387mm with diabetes globally and expected to increase to 592mm by 2035
 - 25% of diabetics will acquire a nonhealing ulcer in their lifetime; ~3mm diabetic ulcers annually



Source:

Wound Care Market. August 2017 MarketsandMarkets

Global Diabetic Foot Ulcers & Pressure Ulcers Market. March 2017. Transparency Market Research

STRATEGIC RELATIONSHIPS



**Exclusive distribution and
license of CBD and hemp
oil chewing gum**



**Equity investment and JV
LOI for Standard
Processing License**



**Research collaboration
for liver diseases**



**Medical cannabis research
& development supply and
collaboration**



**License of cannabidiol for
treatment of Autoimmune
Hepatitis**



**License of cannabinoid
delivery technology**



**Licensed Dealer of
medical cannabis
(R&D, Testing)**

R V V SIGNIFICANTLY UNDERVALUED

TETRA
BIO-PHARMA

\$105 Million
Market Cap

CARDIOL™
THERAPEUTICS

\$100 Million
Market Cap


InMed
Pharmaceuticals

\$40 Million
Market Cap

Potential
\$30 - \$100 Million
Market Cap

10x – 33x return

RVV is between 3% and 7.5%
of TBP, CRDL, IN valuations

 **Revive**
Therapeutics

\$3 Million
Market Cap

TEAM

Management

- **Michael Frank**
Chairman and CEO
- **Carmelo Marrelli**
Chief Financial Officer

Board of Directors

- **Michael Frank**
Chairman and CEO
- **William Jackson**
Director
- **Joshua Herman**
Director
- **Christian Scovenna**
Director
- **Andrew Lindzon**
Director

KEY STOCK INFO

Ticker Symbols

RVV (CSE)

Share Price

CAD \$0.04 (December 19, 2019)

52 week High/Low

CAD \$0.10 / \$0.025

Capital Structure

72,411,282 common shares (90,466,657 fully-diluted)

Market Cap

CAD ~ \$3,00,000

Stock Options: 4,045,375 stock options

(925,000 @ \$0.60; 590,000 @ \$0.66; 40,375 @ \$0.30; 965,000 @ \$0.28; 250,000 @ \$0.20; 350,000 @ \$0.325; 350,000 @ \$0.205; 75,000 @ \$0.205; 500,000 @ \$0.19)

Warrants: 14,010,000 warrants @ \$0.15, Expiring February 2021.